FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783703583> ?p ?o ?g. }

• W2783703583 abstract "Vitiligo development in melanoma patients during immunotherapy is a favorable prognostic sign and indicates breakage of tolerance against melanocytic/melanoma antigens. We investigated a novel immunotherapeutic approach of the skin-depigmenting compound monobenzone synergizing with imiquimod in inducing antimelanoma immunity and melanoma regression. Stage III-IV melanoma patients with non-resectable cutaneous melanoma metastases were treated with monobenzone and imiquimod (MI) therapy applied locally to cutaneous metastases and adjacent skin during 12 weeks, or longer. Twenty-one of 25 enrolled patients were evaluable for clinical assessment at 12 weeks. MI therapy was well-tolerated. Partial regression of cutaneous metastases was observed in 8 patients and stable disease in 1 patient, reaching the statistical endpoint of treatment efficacy. Continued treatment induced clinical response in 11 patients, including complete responses in three patients. Seven patients developed vitiligo-like depigmentation on areas of skin that were not treated with MI therapy, indicating a systemic effect of MI therapy. Melanoma-specific antibody responses were induced in 7 of 17 patients tested and melanoma-specific CD8+T-cell responses in 11 of 15 patients tested. These systemic immune responses were significantly increased during therapy as compared to baseline in responding patients. This study shows that MI therapy induces local and systemic anti-melanoma immunity and local regression of cutaneous metastases in 38% of patients, or 52% during prolonged therapy. This study provides proof-of-concept of MI therapy, a low-cost, broadly applicable and well-tolerated treatment for cutaneous melanoma metastases, attractive for further clinical investigation." @default.
• W2783703583 created "2018-01-26" @default.
• W2783703583 creator A5008161887 @default.
• W2783703583 creator A5011811043 @default.
• W2783703583 creator A5020107252 @default.
• W2783703583 creator A5021731198 @default.
• W2783703583 creator A5025601302 @default.
• W2783703583 creator A5025921282 @default.
• W2783703583 creator A5032088422 @default.
• W2783703583 creator A5035565968 @default.
• W2783703583 creator A5044380946 @default.
• W2783703583 creator A5057667502 @default.
• W2783703583 creator A5058061659 @default.
• W2783703583 creator A5067479381 @default.
• W2783703583 creator A5069097712 @default.
• W2783703583 creator A5071786603 @default.
• W2783703583 creator A5078825146 @default.
• W2783703583 creator A5078825684 @default.
• W2783703583 creator A5084732202 @default.
• W2783703583 date "2018-01-15" @default.
• W2783703583 modified "2023-10-18" @default.
• W2783703583 title "Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial" @default.
• W2783703583 cites W1490978052 @default.
• W2783703583 cites W1550963943 @default.
• W2783703583 cites W1565190053 @default.
• W2783703583 cites W1569097370 @default.
• W2783703583 cites W1856691397 @default.
• W2783703583 cites W1944300754 @default.
• W2783703583 cites W1976588894 @default.
• W2783703583 cites W1983212277 @default.
• W2783703583 cites W1988607812 @default.
• W2783703583 cites W1999994416 @default.
• W2783703583 cites W2003574010 @default.
• W2783703583 cites W2005064613 @default.
• W2783703583 cites W2009865483 @default.
• W2783703583 cites W2019607817 @default.
• W2783703583 cites W2025558159 @default.
• W2783703583 cites W2035928591 @default.
• W2783703583 cites W2038030122 @default.
• W2783703583 cites W2047491570 @default.
• W2783703583 cites W2050343553 @default.
• W2783703583 cites W2069384112 @default.
• W2783703583 cites W2080914877 @default.
• W2783703583 cites W2087857265 @default.
• W2783703583 cites W2088481794 @default.
• W2783703583 cites W2089738194 @default.
• W2783703583 cites W2095406487 @default.
• W2783703583 cites W2100158834 @default.
• W2783703583 cites W2103371315 @default.
• W2783703583 cites W2103876938 @default.
• W2783703583 cites W2109274792 @default.
• W2783703583 cites W2111180747 @default.
• W2783703583 cites W2113132543 @default.
• W2783703583 cites W2118274777 @default.
• W2783703583 cites W2118863192 @default.
• W2783703583 cites W2119793175 @default.
• W2783703583 cites W2120113475 @default.
• W2783703583 cites W2127392162 @default.
• W2783703583 cites W2132916434 @default.
• W2783703583 cites W2135732415 @default.
• W2783703583 cites W2136805609 @default.
• W2783703583 cites W2140940913 @default.
• W2783703583 cites W2152093797 @default.
• W2783703583 cites W2152166232 @default.
• W2783703583 cites W2189727703 @default.
• W2783703583 cites W2320718432 @default.
• W2783703583 cites W2510940771 @default.
• W2783703583 cites W270984851 @default.
• W2783703583 cites W4238725774 @default.
• W2783703583 doi "https://doi.org/10.1080/2162402x.2017.1419113" @default.
• W2783703583 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5889200" @default.
• W2783703583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29632737" @default.
• W2783703583 hasPublicationYear "2018" @default.
• W2783703583 type Work @default.
• W2783703583 sameAs 2783703583 @default.
• W2783703583 citedByCount "26" @default.
• W2783703583 countsByYear W27837035832018 @default.
• W2783703583 countsByYear W27837035832019 @default.
• W2783703583 countsByYear W27837035832020 @default.
• W2783703583 countsByYear W27837035832021 @default.
• W2783703583 countsByYear W27837035832022 @default.
• W2783703583 countsByYear W27837035832023 @default.
• W2783703583 crossrefType "journal-article" @default.
• W2783703583 hasAuthorship W2783703583A5008161887 @default.
• W2783703583 hasAuthorship W2783703583A5011811043 @default.
• W2783703583 hasAuthorship W2783703583A5020107252 @default.
• W2783703583 hasAuthorship W2783703583A5021731198 @default.
• W2783703583 hasAuthorship W2783703583A5025601302 @default.
• W2783703583 hasAuthorship W2783703583A5025921282 @default.
• W2783703583 hasAuthorship W2783703583A5032088422 @default.
• W2783703583 hasAuthorship W2783703583A5035565968 @default.
• W2783703583 hasAuthorship W2783703583A5044380946 @default.
• W2783703583 hasAuthorship W2783703583A5057667502 @default.
• W2783703583 hasAuthorship W2783703583A5058061659 @default.
• W2783703583 hasAuthorship W2783703583A5067479381 @default.
• W2783703583 hasAuthorship W2783703583A5069097712 @default.
• W2783703583 hasAuthorship W2783703583A5071786603 @default.
• W2783703583 hasAuthorship W2783703583A5078825146 @default.
• W2783703583 hasAuthorship W2783703583A5078825684 @default.
• W2783703583 hasAuthorship W2783703583A5084732202 @default.

• next